{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:58:14Z","timestamp":1785322694949,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109772","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:51:52Z","timestamp":1773906712000},"page":"109772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Towards the discovery of potent epigenetic modulators: Design, synthesis, biological evaluation, and SAR investigation of novel indole-based derivatives targeting HDAC1 and HDAC6"],"prefix":"10.1016","volume":"175","author":[{"given":"Sarah","family":"Shawky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek Erfan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Haffez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sobhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Soror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiy","family":"Jaballah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermin","family":"Samir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Henary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena S.","family":"Lasheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109772_bb0005","first-page":"1783","article-title":"The epigenetic hallmarks of Cancer, Cancer","volume":"14","author":"Esteller","year":"2024","journal-title":"Discovery"},{"key":"10.1016\/j.bioorg.2026.109772_bb0010","first-page":"1954","article-title":"Epigenetic mechanisms and the hallmarks of cancer: an intimate affair","volume":"10","author":"Darwiche","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109772_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bioorg.2026.109772_bb0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1586\/era.10.62","article-title":"Nonhistone protein acetylation as cancer therapy targets","volume":"10","author":"Singh","year":"2010","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bioorg.2026.109772_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.700947","article-title":"Characterization of histone deacetylase mechanisms in Cancer development","volume":"11","author":"Hai","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109772_bb0030","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/cells9030780","article-title":"Role of histone deacetylases in carcinogenesis: potential role in cholangiocarcinoma","volume":"9","author":"Pant","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.109772_bb0035","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109772_bb0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109772_bb0045","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1021\/acs.jmedchem.2c00687","article-title":"Therapeutic potential and activity modulation of the protein lysine Deacylase Sirtuin 5","volume":"65","author":"Fiorentino","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116696","article-title":"Overview of class I HDAC modulators: inhibitors and degraders","volume":"276","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06205-0","article-title":"Targeting the E2F1\/Rb\/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth","volume":"14","author":"Duan","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.109772_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2604-7","article-title":"HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma","volume":"16","author":"Ramakrishnan","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.109772_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116571","article-title":"Advances in dual-targeting inhibitors of HDAC6 for cancer treatment","volume":"275","author":"Gu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0070","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0075","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.3390\/molecules26175151","article-title":"Non-Hydroxamate zinc-binding groups as warheads for histone deacetylases","volume":"26","author":"Fr\u00fchauf","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109772_bb0080","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1016\/j.bmcl.2016.08.073","article-title":"Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy","volume":"26","author":"Jiao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109772_bb0085","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109772_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.53388\/PD202505008","article-title":"Recent progress of small molecular HDAC modulators for cancer therapy and beyond","volume":"5","author":"Zhao","year":"2025","journal-title":"Pharmacol. Discov."},{"key":"10.1016\/j.bioorg.2026.109772_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109772_bb0100","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.bmc.2013.04.036","article-title":"Structural basis for the design and synthesis of selective HDAC inhibitors","volume":"21","author":"Di Micco","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0105","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"23","author":"Ryan","year":"2005","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109772_bb0110","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109772_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejmech.2018.02.065","article-title":"Indole in the target-based design of anticancer agents: a versatile scaffold with diverse mechanisms","volume":"150","author":"Dadashpour","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106622","article-title":"Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: structure, function and design","volume":"138","author":"Peng","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0125","doi-asserted-by":"crossref","first-page":"35402","DOI":"10.1074\/jbc.M807045200","article-title":"Pimelic Diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases","volume":"283","author":"Chou","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0130","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1021\/acs.jmedchem.8b01936","article-title":"Selective inhibition of histone deacetylase 10: hydrogen bonding to the gatekeeper residue is implicated","volume":"62","author":"G\u00e9raldy","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115040","article-title":"SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against gram-negative bacteria","volume":"247","author":"Dokla","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-023-01101-2","article-title":"Targeting apoptosis; design, synthesis and biological evaluation of new benzoxazole and thiazole based derivatives","volume":"18","author":"Helmy","year":"2024","journal-title":"BMC Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0145","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1021\/acs.jcim.6b00795","article-title":"Potent Pan-Raf and receptor tyrosine kinase inhibitors based on a Cyclopropyl Formamide fragment overcome resistance","volume":"57","author":"Zhang","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.109772_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105451","article-title":"Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer","volume":"117","author":"Dokla","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0155","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/jhet.5570140701","article-title":"The reaction of indole and the indole grignard reagent with phosgene. A facile synthesis of indole-3-carboxylic acid derivatives","volume":"14","author":"Bergman","year":"1977","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117680","article-title":"Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC\/non-covalent proteasome inhibitors","volume":"104","author":"Chan","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0165","series-title":"Novel solid forms of tacedinaline, US20140275268A1","author":"Holson","year":"2014"},{"key":"10.1016\/j.bioorg.2026.109772_bb0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejps.2018.08.030","article-title":"Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects","volume":"124","author":"Trivedi","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109772_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105724","article-title":"HDAC1\/MAO-B dual inhibitors against Alzheimer's disease: design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid\/o-aminobenzamide hybrids","volume":"122","author":"Yao","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116251","article-title":"Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents","volume":"42","author":"El-Awady","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0185","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/carcin\/bgi253","article-title":"Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?","volume":"27","author":"Dashwood","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2026.109772_bb0190","article-title":"Anticancer study of a novel Pan-HDAC inhibitor MPT0G236 in colorectal Cancer cells","volume":"24","author":"Tsai","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2026.109772_bb0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/epi.3.1.5736","article-title":"HDACs and HDAC inhibitors in colon cancer","volume":"3","author":"Mariadason","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.bioorg.2026.109772_bb0200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/atm.2018.11.48","article-title":"Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells","volume":"7","author":"Tan","year":"2019","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.bioorg.2026.109772_bb0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.18869\/nirp.bcn.8.4.325","article-title":"The role of protein kinase B signaling pathway in anti-cancer effect of Rolipram on glioblastoma Multiforme: an in vitro study","volume":"8","author":"Ramezani","year":"2017","journal-title":"BCN"},{"key":"10.1016\/j.bioorg.2026.109772_bb0210","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109772_bb0215","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.7164\/antibiotics.53.1191","article-title":"Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells","volume":"53","author":"Kim","year":"2000","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bioorg.2026.109772_bb0220","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/jm7011408","article-title":"Histone deacetylase inhibitors: from bench to clinic","volume":"51","author":"Paris","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0225","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0026-895X(25)09073-X","article-title":"Cell cycle-dependent cytotoxicity, G2\/M phase arrest, and disruption of p34cdc2\/cyclin B1 activity induced by doxorubicin in synchronized P388 cells","volume":"49","author":"Ling","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109772_bb0230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14499\/indonesianjcanchemoprev8iss2pp61-67","article-title":"Doxorubicin induces Lamellipodia formation and cell migration","volume":"8","author":"Amalina","year":"2017","journal-title":"IJCC"},{"key":"10.1016\/j.bioorg.2026.109772_bb0235","doi-asserted-by":"crossref","first-page":"12.8.1","DOI":"10.1002\/0471141755.ph1208s25","article-title":"Measurement of cell death in mammalian cells","volume":"25","author":"Cummings","year":"2004","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109772_bb0240","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1074\/jbc.M508342200","article-title":"Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells","volume":"281","author":"Patel","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0245","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.3390\/cancers13184700","article-title":"Vorinostat (SAHA) and breast Cancer: an overview","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109772_bb0250","series-title":"Encyclopedia of Cancer","first-page":"3191","article-title":"Vorinostat","author":"Richon","year":"2009"},{"key":"10.1016\/j.bioorg.2026.109772_bb0255","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"Bolden","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.109772_bb0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1701848114","article-title":"Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery","volume":"114","author":"Mateus","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.109772_bb0265","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/03602532.2018.1512614","article-title":"Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery","volume":"50","author":"Li","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bioorg.2026.109772_bb0270","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3390\/molecules30173630","article-title":"Comparative analysis of biochemical and cellular assay conditions and the need for a buffer that mimics cytoplasmic environments","volume":"30","author":"Kontopidis","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109772_bb0275","article-title":"DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism","volume":"11","author":"Bell","year":"2019","journal-title":"J. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0280","unstructured":"NCI-60 Screening Methodology | NCI-60 Human Tumor Cell Lines Screen | Discovery & Development Services | Developmental Therapeutics Program (DTP), (n.d.). https:\/\/dtp.cancer.gov\/discovery_development\/nci-60\/methodology.htm (accessed May 5, 2025)."},{"key":"10.1016\/j.bioorg.2026.109772_bb0285","series-title":"Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting","author":"Motulsky","year":"2004"},{"key":"10.1016\/j.bioorg.2026.109772_bb0290","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3390\/molecules26020506","article-title":"Revealing the potential application of EC-synthetic retinoid analogues in anticancer therapy","volume":"26","author":"Abdelaal","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109772_bb0295","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.220001","article-title":"The potential roles of retinoids in combating drug resistance in cancer: implications of ATP-binding cassette (ABC) transporters","volume":"12","author":"Abdelaal","year":"2022","journal-title":"Open Biol."},{"key":"10.1016\/j.bioorg.2026.109772_bb0300","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.3390\/ijms23169442","article-title":"Augmented therapeutic potential of EC-synthetic Retinoids in Caco-2 Cancer cells using an in vitro approach","volume":"23","author":"Abdelaal","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2026.109772_bb0305","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.bioorg.2026.109772_bb0310","article-title":"Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal Cancer HCT116 cells in vitro and in vivo","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2026.109772_bb0315","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1111\/jcmm.17924","article-title":"Epigenetic histone modification by butyrate downregulates KIT and attenuates mast cell function","volume":"27","author":"Gudneppanavar","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109772_bb0320","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.3390\/ijms24109015","article-title":"Dietary supplementation of inulin contributes to the prevention of estrogen receptor-negative mammary Cancer by alteration of gut microbial communities and epigenetic regulations","volume":"24","author":"Wu","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2026.109772_bb0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.109772_bb0330","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.109772_bb0335","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/ci500209e","article-title":"AutoDock4Zn\u00a0: an improved AutoDock force field for small-molecule docking to zinc Metalloproteins","volume":"54","author":"Santos-Martins","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.109772_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class I HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat. Commun."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:14:29Z","timestamp":1776111269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826003081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"alternative-id":["S0045206826003081"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109772","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards the discovery of potent epigenetic modulators: Design, synthesis, biological evaluation, and SAR investigation of novel indole-based derivatives targeting HDAC1 and HDAC6","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109772"}}